Flu Season Alert!Alerta de temporada de influenza:
Don’t let germs win this season – protect yourself and your family!
The flu vaccine is your best defense against flu and related complications – PLUS, it is a covered benefit for Texas Children’s Health Plan members! Learn more!
¡No permitas que los gérmenes ganen esta temporada! ¡Protégete a ti y a tu familia!
La vacuna contra la influenza es tu mejor defensa contra la influenza y sus complicaciones. Además, ¡es un beneficio cubierto para los miembros de Texas Children's Health Plan! Aprende más
Addition of Paxlovid (Pfizer Oral Covid-19 Drug) to Formulary
Date: January 8, 2024
Attention: Providers
Effective date: January 4, 2024
Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective January 4, 2024, the Texas Health and Human Services (HHS) added Paxlovid to the formulary.
Paxlovid (nirmatrelvir co-packaged with ritonavir) is an oral antiviral tablet, is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
How this impacts providers:
Please see below for the list of impacted drugs (of note, the approval is NDC-specific):
Medication
Medication NDC
Type of Change
Effective Date
PAXLOVID 150-100 MG DOSE PACK
00069531720
FORMULARY ADDITION
January 4, 2024
PAXLOVID 300-100 MG DOSE PACK
00069532130
FORMULARY ADDITION
January 4, 2024
Next step for Providers: Prescribers are encouraged to educate patients about Paxlovid, including the importance of early intervention and adherence to prescribed treatment regimens. For detailed information on Paxlovid, including prescribing information and eligibility criteria, please refer to the drug’s official prescribing information.
